邦顺制药递表港交所
Zhi Tong Cai Jing·2026-01-22 11:46
Group 1 - Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange on January 22, with CITIC Securities International as the sole sponsor [1] - The company is a biotechnology firm nearing commercialization, focusing on oncology and autoimmune diseases [1] - Bangshun Pharmaceutical has established a pipeline that includes one drug candidate in the New Drug Application (NDA) stage (Bezafibrate), one drug candidate in the registration clinical stage (CX1440), and five drug candidates in the preclinical stage (CX03, CX12, CX13, CX15, and CX16) [1]